Achalasia

Reading File

Finding Sources

Searching PubMed

achalasia diagnosis treatment

Reading File

Finding Sources

Reading File

Loading Image

I have all the information needed for a comprehensive answer. Let me now compile the full response.

Achalasia

Definition and Epidemiology

Achalasia is an esophageal motility disorder defined by two cardinal physiologic abnormalities: impaired lower esophageal sphincter (LES) relaxation with swallowing and aperistalsis in the smooth muscle esophagus. It is rare, with a population incidence of 1-3 per 100,000, and typically presents between ages 25 and 60. - Harrison's Principles of Internal Medicine, 22E

Pathophysiology

The underlying defect is loss of ganglion cells in the myenteric (Auerbach) plexus of the esophageal smooth muscle, including the LES. Key features:

The inflammatory infiltrate in the myenteric plexus consists predominantly of cytotoxic T cells, pointing to an autoimmune process in genetically susceptible individuals
Increasing evidence implicates a latent infection with HSV-1 as the trigger
Both excitatory (cholinergic) and inhibitory (nitric oxide/VIP) neurons are affected
Inhibitory neuron loss is the early hallmark - these neurons normally mediate deglutitive LES relaxation and peristaltic propagation
Loss of NO synthase and VIP-staining neurons at the gastroesophageal junction is characteristic
Disease likely progresses: EGJ outflow obstruction → Type II → Type I → end-stage dilated achalasia
Type III has a distinct mechanism: myenteric plexus inflammation and altered function without frank destruction
Sleisenger and Fordtran's Gastrointestinal and Liver Disease

Chicago Classification - HRM Subtypes

High-resolution manometry (HRM) subclassifies achalasia into 3 types with therapeutic implications:

Type	Features	Response to Therapy
Type I - Classic	Aperistalsis, minimal pressurization; dilated esophagus	Intermediate
Type II - With compression	Pan-esophageal pressurization ≥20% of swallows	Best (100% with pneumatic dilation in European trial)
Type III - Spastic	Premature/spastic contractions, preserved LES; distal spasm	Worst with dilation (40%); better with myotomy (86%)

Types I and II represent a continuum (type II being earlier disease); type III is pathogenetically distinct. - Sleisenger & Fordtran's

Clinical Features

Symptom	Notes
Dysphagia (100%)	Both solids and liquids; gradual onset, often years before diagnosis
Regurgitation (~70%)	Non-bilious, non-acid; food eaten hours or days earlier; mixed with saliva
Chest pain (~40-50%)	Early in disease; may mimic angina; often spontaneously improves with time
Heartburn (~40-50%)	Not true reflux - caused by fermentation of retained food in esophagus
Weight loss	Variable
Aspiration pneumonia	Up to 10% with advanced disease
Halitosis, hiccups	Due to food stasis

The "heartburn" in achalasia is a diagnostic trap - patients are often treated for "refractory GERD" for years, delaying the correct diagnosis. Ambulatory pH studies show acidification from bacterial fermentation, not true GER events. - Sabiston Textbook of Surgery

The Eckardt Score quantifies severity (0-3 points each for dysphagia, regurgitation, weight loss, chest pain; total 0-12). A score ≤3 indicates successful treatment. - Sabiston

Diagnostic Workup

1. Esophagogastroduodenoscopy (EGD)

Performed first to exclude pseudoachalasia (tumor infiltration, stricture)
Findings: retained food/saliva (60%), stasis esophagitis, Candida infection
In idiopathic achalasia, the endoscope should "pop through" the EGJ with only gentle pressure - resistance suggests pseudoachalasia
Up to 40% of cases are endoscopically normal

2. Barium Swallow

Barium swallow in achalasia showing classic "bird-beak" tapering at the LES with esophageal dilation

Barium swallow showing dilated esophagus with distal tapering (bird-beak sign), air-fluid level, and slow contrast emptying. - Sabiston Textbook of Surgery

Classic findings:

Dilated esophagus with smooth, tapered "bird-beak" narrowing at LES
Air-fluid level
Poor emptying of contrast into stomach
Tertiary (non-peristaltic) contractions
In advanced disease: sigmoid esophagus (massively dilated, S-shaped)
Normal in ~30% of early cases

Barium swallow in achalasia - dilated esophagus and sigmoid deformity in advanced disease (Harrison's)

3. High-Resolution Esophageal Manometry (HRM) - Gold Standard

Diagnostic criteria:

Absent peristalsis in the smooth muscle esophagus (100% failed peristalsis)
Impaired LES relaxation (elevated integrated relaxation pressure, IRP)
Subtype classification (Types I, II, III above)

HRM is the gold standard for both establishing the diagnosis and defining the subtype for treatment planning. - Sabiston Textbook of Surgery

Differential Diagnosis

Condition	Key Distinguishing Features
Pseudoachalasia	Age >50, symptoms <1 year, weight loss >7 kg; EGD, CT, or EUS shows tumor
Chagas disease	Endemic area (Brazil, Venezuela, Argentina); T. cruzi serology; additional organ involvement (megacolon, cardiomyopathy)
Distal Esophageal Spasm (DES)	Preserved LES relaxation (vs. type III achalasia)
Opioid-induced dysmotility	History of chronic opioid use
Post-surgical pseudoachalasia	After fundoplication or gastric banding

Treatment

Since the underlying neuropathology cannot be corrected, treatment aims to reduce LES pressure to allow gravity-assisted emptying.

Pharmacologic (temporizing only)

Calcium channel blockers (nifedipine 30-40 mg/day sublingual before meals) or nitrates (isosorbide dinitrate) - modest benefit, significant side effects (headache, flushing, orthostasis)
Sildenafil 50 mg - blocks PDE-5, reduces LES pressure; practical use limited by cost and side effects
All pharmacologic options are considered temporizing, not definitive

Botulinum Toxin Injection

Intrasphincteric injection of 80-100 units into 4 LES quadrants
Initial response in ~66%, but minimal continued efficacy at 1 year
Repeat injections cause local fibrosis, limiting this strategy long-term
Best reserved for elderly or frail patients who are poor candidates for definitive treatment

Pneumatic Dilation

Uses Rigiflex balloons (3.0, 3.5, or 4.0 cm) to mechanically disrupt LES circular muscle
Requires dilation to ≥3 cm diameter for lasting benefit
Success rate ~90% comparable to laparoscopic Heller myotomy
Perforation risk ~1%
Preferred initial therapy for Type II achalasia (100% success in European Achalasia Trial)
Less effective in Type III (40% success)
Can be repeated if initial dilation fails

Laparoscopic Heller Myotomy (LHM)

Division of LES circular muscle; typically combined with partial fundoplication (Dor or Toupet) to prevent reflux
Success rate ~87-92%
Preferred for Type III achalasia (86% success)
The European Achalasia Trial (200 patients, RCT) showed no statistically significant difference between pneumatic dilation and LHM at 2-year follow-up

Per Oral Endoscopic Myotomy (POEM)

Endoscopic approach: submucosal tunnel created in mid-esophagus → selective circular myotomy extending 2 cm onto gastric cardia
Success rate >90%, comparable to or better than LHM short-term
A meta-analysis (POEM n=1958 vs. LHM n=5834) showed POEM more effective for dysphagia but with significantly higher pathological reflux (OR 9.31 for erosive esophagitis)
RCT: 92% POEM vs. 70% pneumatic dilation at 1 year (p<0.01)
Particular advantage for Type III achalasia where the myotomy length can be extended the full length of the spastic segment

Treatment Selection Summary

Subtype	Preferred Treatment
Type I	Pneumatic dilation or LHM
Type II	Pneumatic dilation (first-line)
Type III	LHM or POEM (preferred over dilation)
Elderly/frail	Botulinum toxin
End-stage/sigmoid	Consider esophagectomy

Sleisenger and Fordtran's Gastrointestinal and Liver Disease

Complications

Aspiration pneumonia (up to 10% with advanced disease)
Stasis esophagitis and Candida esophagitis
Epiphrenic diverticulum
Squamous cell carcinoma - 17-fold increased risk vs. age-matched controls; typically develops in massively dilated esophagus with long-standing disease. Absolute risk ~0.15%; ASGE does not recommend routine surveillance, but if considered, to begin 15 years after symptom onset
Post-treatment GERD - especially after POEM and LHM without fundoplication

Treatment Failure Evaluation

Persistent dysphagia after treatment should be evaluated with:

Endoscopy (esophagitis, stricture, anatomic deformity)
High-resolution impedance manometry (persistent sphincter dysfunction, spasm)
Functional luminal imaging probe (FLIP)
Fluoroscopic timed barium esophagogram

Sources: Sleisenger and Fordtran's Gastrointestinal and Liver Disease; Harrison's Principles of Internal Medicine 22E; Sabiston Textbook of Surgery; Current Surgical Therapy 14e

Can u write it in one pdf

Reading File

Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "created"

Running Command

mkdir -p /tmp/workspace/achalasia && cat > /tmp/workspace/achalasia/generate_pdf.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, KeepTogether) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY from reportlab.platypus import Image as RLImage import urllib.request import os OUTPUT = "/tmp/workspace/achalasia/Achalasia.pdf" # Download images img_urls = { "barium_beak.png": "https://cdn.orris.care/cdss_images/88d75d9f2aa3f3c7e8542817eae9e19ad684b5f5dd3fd6efcf435fc91a822f03.png", "barium_dilated.png": "https://cdn.orris.care/cdss_images/9e70e075a3ba4803e3599df15266df04a5df8bf6ec841b04e87f2c30ae81e1ae.png", } for fname, url in img_urls.items(): fpath = f"/tmp/workspace/achalasia/{fname}" if not os.path.exists(fpath): urllib.request.urlretrieve(url, fpath) print(f"Downloaded {fname}") doc = SimpleDocTemplate( OUTPUT, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2*cm, bottomMargin=2*cm, title="Achalasia - Comprehensive Clinical Review", author="Orris Medical Library" ) W = A4[0] - 4*cm # usable width styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle( "MainTitle", fontName="Helvetica-Bold", fontSize=22, textColor=colors.HexColor("#1a3a5c"), spaceAfter=4, spaceBefore=0, alignment=TA_CENTER, ) subtitle_style = ParagraphStyle( "Subtitle", fontName="Helvetica", fontSize=10, textColor=colors.HexColor("#555555"), spaceAfter=10, alignment=TA_CENTER, ) h1_style = ParagraphStyle( "H1", fontName="Helvetica-Bold", fontSize=13, textColor=colors.white, spaceAfter=6, spaceBefore=12, leftIndent=6, ) h2_style = ParagraphStyle( "H2", fontName="Helvetica-Bold", fontSize=11, textColor=colors.HexColor("#1a3a5c"), spaceAfter=4, spaceBefore=8, ) body_style = ParagraphStyle( "Body", fontName="Helvetica", fontSize=9.5, textColor=colors.HexColor("#222222"), spaceAfter=4, leading=14, alignment=TA_JUSTIFY, ) bullet_style = ParagraphStyle( "Bullet", fontName="Helvetica", fontSize=9.5, textColor=colors.HexColor("#222222"), spaceAfter=3, leading=13, leftIndent=14, bulletIndent=4, ) caption_style = ParagraphStyle( "Caption", fontName="Helvetica-Oblique", fontSize=8.5, textColor=colors.HexColor("#555555"), spaceAfter=6, alignment=TA_CENTER, ) source_style = ParagraphStyle( "Source", fontName="Helvetica-Oblique", fontSize=8, textColor=colors.HexColor("#777777"), spaceAfter=2, alignment=TA_RIGHT, ) callout_style = ParagraphStyle( "Callout", fontName="Helvetica-Oblique", fontSize=9, textColor=colors.HexColor("#1a3a5c"), leftIndent=10, rightIndent=10, spaceAfter=6, leading=13, borderPad=6, ) BLUE = colors.HexColor("#1a3a5c") LIGHT_BLUE = colors.HexColor("#dce8f5") TEAL = colors.HexColor("#1a7a7a") HEADER_BG = colors.HexColor("#1a3a5c") ALT_ROW = colors.HexColor("#f0f5fb") def section_header(text): """Returns a blue-background section header block.""" tbl = Table([[Paragraph(text, h1_style)]], colWidths=[W]) tbl.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), BLUE), ("TOPPADDING", (0,0), (-1,-1), 5), ("BOTTOMPADDING", (0,0), (-1,-1), 5), ("LEFTPADDING", (0,0), (-1,-1), 8), ("ROUNDEDCORNERS", [4,4,4,4]), ])) return tbl def make_table(headers, rows, col_widths=None): if col_widths is None: col_widths = [W / len(headers)] * len(headers) header_row = [Paragraph(f"{h}", ParagraphStyle("TH", fontName="Helvetica-Bold", fontSize=9, textColor=colors.white, alignment=TA_CENTER)) for h in headers] data = [header_row] for i, row in enumerate(rows): styled_row = [Paragraph(cell, ParagraphStyle("TD", fontName="Helvetica", fontSize=9, textColor=colors.HexColor("#222"), leading=12)) for cell in row] data.append(styled_row) tbl = Table(data, colWidths=col_widths, repeatRows=1) style = [ ("BACKGROUND", (0,0), (-1,0), BLUE), ("ROWBACKGROUNDS", (0,1), (-1,-1), [colors.white, ALT_ROW]), ("GRID", (0,0), (-1,-1), 0.4, colors.HexColor("#cccccc")), ("TOPPADDING", (0,0), (-1,-1), 5), ("BOTTOMPADDING", (0,0), (-1,-1), 5), ("LEFTPADDING", (0,0), (-1,-1), 6), ("VALIGN", (0,0), (-1,-1), "TOP"), ] tbl.setStyle(TableStyle(style)) return tbl def callout_box(text): tbl = Table([[Paragraph(text, callout_style)]], colWidths=[W]) tbl.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), LIGHT_BLUE), ("LEFTPADDING", (0,0), (-1,-1), 10), ("RIGHTPADDING", (0,0), (-1,-1), 10), ("TOPPADDING", (0,0), (-1,-1), 8), ("BOTTOMPADDING", (0,0), (-1,-1), 8), ("BOX", (0,0), (-1,-1), 1.5, BLUE), ])) return tbl story = [] # ── TITLE ────────────────────────────────────────────────────────────────── story.append(Spacer(1, 0.3*cm)) story.append(Paragraph("ACHALASIA", title_style)) story.append(Paragraph("Comprehensive Clinical Review", subtitle_style)) story.append(HRFlowable(width=W, thickness=2, color=BLUE, spaceAfter=8)) # Sources line story.append(Paragraph( "Sources: Sleisenger & Fordtran's GI and Liver Disease · Harrison's Principles (22E) · Sabiston Textbook of Surgery · Current Surgical Therapy 14e", source_style )) story.append(Spacer(1, 0.3*cm)) # ── 1. DEFINITION & EPIDEMIOLOGY ─────────────────────────────────────────── story.append(section_header("1. Definition & Epidemiology")) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "Achalasia is an esophageal motility disorder defined by two cardinal physiologic abnormalities: " "impaired lower esophageal sphincter (LES) relaxation with swallowing and aperistalsis in the smooth " "muscle esophagus. When premature, spastic contractions occur in the esophageal body, the condition is " "referred to as spastic (Type III) achalasia.", body_style )) story.append(Paragraph( "It is a rare disease with a population incidence of 1–3 per 100,000, presenting typically between " "ages 25 and 60. There is no clear sex predilection.", body_style )) story.append(Spacer(1, 0.2*cm)) # ── 2. PATHOPHYSIOLOGY ───────────────────────────────────────────────────── story.append(section_header("2. Pathophysiology")) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "The underlying defect is loss of ganglion cells in the myenteric (Auerbach) plexus of the " "esophageal smooth muscle and LES. Histological analysis shows mononuclear inflammatory infiltrates " "surrounding residual ganglion cells, predominantly cytotoxic T cells.", body_style )) story.append(Spacer(1, 0.1*cm)) for b in [ "Both excitatory (cholinergic) and inhibitory (nitric oxide/VIP) neurons are affected — inhibitory neuron loss is the earliest detectable abnormality", "Loss of NO synthase and VIP-staining neurons at the gastroesophageal junction is characteristic", "Increasing evidence implicates an autoimmune process triggered by latent HSV-1 infection in genetically susceptible individuals", "Disease likely progresses: EGJ outflow obstruction → Type II → Type I → end-stage dilated achalasia", "Type III has a distinct mechanism: plexus inflammation and altered function without frank destruction", "The degree of ganglion cell loss parallels disease duration", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.2*cm)) # ── 3. CHICAGO CLASSIFICATION ────────────────────────────────────────────── story.append(section_header("3. Chicago Classification (HRM Subtypes)")) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "High-resolution manometry (HRM) subclassifies achalasia into 3 subtypes with distinct therapeutic implications:", body_style )) story.append(Spacer(1, 0.15*cm)) story.append(make_table( ["Type", "HRM Features", "Response to Treatment"], [ ["Type I — Classic", "Aperistalsis; minimal pressurization; dilated esophagus", "Intermediate; ~80–90%"], ["Type II — With compression", "Pan-esophageal pressurization ≥20% swallows; no dilatation", "Best — 100% with pneumatic dilation (European trial)"], ["Type III — Spastic", "Premature/spastic contractions; preserved LES; distal spasm", "Worst with dilation (40%); better with myotomy (86%)"], ], col_widths=[W*0.18, W*0.42, W*0.40] )) story.append(Spacer(1, 0.15*cm)) story.append(callout_box( "Types I and II represent a continuum (type II being earlier disease before esophageal dilatation). " "Type III is pathogenetically distinct and responds poorly to pneumatic dilation." )) story.append(Spacer(1, 0.2*cm)) # ── 4. CLINICAL FEATURES ─────────────────────────────────────────────────── story.append(section_header("4. Clinical Features")) story.append(Spacer(1, 0.2*cm)) story.append(make_table( ["Symptom", "Prevalence", "Notes"], [ ["Dysphagia", "100%", "Both solids AND liquids; gradual onset; often present years before diagnosis"], ["Regurgitation", "~70%", "Non-bilious, non-acid; food from hours/days prior; mixed with saliva"], ["Chest pain", "~40–50%", "Early in disease; pressure-like, may radiate; spontaneously improves with time"], ["Heartburn", "~40–50%", "NOT true reflux — caused by fermentation of retained food (diagnostic trap)"], ["Weight loss", "Variable", "Progressive with advanced disease"], ["Aspiration pneumonia", "Up to 10%", "With advanced disease; can be the presenting complaint"], ["Halitosis / hiccups", "Variable", "Due to food stasis in dilated esophagus"], ], col_widths=[W*0.22, W*0.16, W*0.62] )) story.append(Spacer(1, 0.15*cm)) story.append(callout_box( "Diagnostic Trap: Many achalasia patients complain of \"heartburn\" and are treated for refractory GERD for years. " "Ambulatory pH studies show esophageal acidification from bacterial fermentation of retained food — not true GER events. " "Lack of response to PPIs should prompt motility evaluation." )) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("Eckardt Score (assesses severity and treatment response):", h2_style)) story.append(make_table( ["Symptom", "0", "1", "2", "3"], [ ["Dysphagia", "None", "Occasional", "Daily", "Each meal"], ["Regurgitation", "None", "Occasional", "Daily", "Each meal"], ["Chest pain", "None", "Occasional", "Daily", "Each meal"], ["Weight loss (kg)", "None", "<5", "5–10", ">10"], ], col_widths=[W*0.30, W*0.175, W*0.175, W*0.175, W*0.175] )) story.append(Paragraph("Score ≤3 = successful treatment. Total range: 0–12.", body_style)) story.append(Spacer(1, 0.2*cm)) # ── 5. DIAGNOSTIC WORKUP ─────────────────────────────────────────────────── story.append(section_header("5. Diagnostic Workup")) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("5.1 Esophagogastroduodenoscopy (EGD)", h2_style)) story.append(Paragraph( "Performed first to exclude pseudoachalasia (tumor infiltration, stricture, malignancy). " "In idiopathic achalasia, the endoscope should 'pop through' the EGJ with only gentle pressure — " "resistance suggests pseudoachalasia.", body_style )) for b in [ "Up to 40% of cases are endoscopically normal", "Other findings: retained food/saliva, stasis esophagitis, Candida esophagitis", "If pseudoachalasia is suspected: obtain CT, MRI, or EUS in addition to biopsy", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("5.2 Barium Swallow", h2_style)) story.append(Paragraph( "Provides anatomical information; normal in ~30% of early cases.", body_style )) # Images side by side img1 = RLImage("/tmp/workspace/achalasia/barium_beak.png", width=W*0.48, height=7.5*cm) img2 = RLImage("/tmp/workspace/achalasia/barium_dilated.png", width=W*0.38, height=7.5*cm) img_tbl = Table([[img1, img2]], colWidths=[W*0.52, W*0.48]) img_tbl.setStyle(TableStyle([ ("ALIGN", (0,0), (-1,-1), "CENTER"), ("VALIGN", (0,0), (-1,-1), "MIDDLE"), ])) story.append(img_tbl) story.append(Paragraph( "LEFT: Achalasia with dilated esophagus showing poor emptying and bird-beak tapering at LES (Harrison's, 22E). " "RIGHT: Barium swallow showing dilated esophagus with distal narrowing, air-fluid level, and slow contrast emptying (Sabiston).", caption_style )) for b in [ "Bird-beak sign: smooth, tapered narrowing at the LES", "Air-fluid level in the dilated esophagus", "Poor emptying of contrast into stomach", "Tertiary (non-peristaltic) contractions", "Sigmoid esophagus in advanced long-standing disease (massively dilated, S-shaped)", "Occasional epiphrenic diverticulum", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("5.3 High-Resolution Esophageal Manometry (HRM) — Gold Standard", h2_style)) story.append(Paragraph( "HRM is the gold standard for both establishing the diagnosis and defining the subtype for treatment planning. " "Diagnostic criteria require:", body_style )) for b in [ "Absent peristalsis in the smooth muscle esophagus (100% failed swallows)", "Impaired LES relaxation — elevated Integrated Relaxation Pressure (IRP) above the 4th percentile of normal", "Subtype classification (I, II, III) based on pressurization pattern", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.2*cm)) # ── 6. DIFFERENTIAL DIAGNOSIS ────────────────────────────────────────────── story.append(section_header("6. Differential Diagnosis")) story.append(Spacer(1, 0.2*cm)) story.append(make_table( ["Condition", "Key Distinguishing Features"], [ ["Pseudoachalasia", "Age >50, symptoms <1 year, weight loss >7 kg; resistance on EGD; CT/EUS/biopsy shows tumor (accounts for ~5% of manometric achalasia cases)"], ["Chagas disease", "Endemic area (Brazil, Venezuela, Argentina); Trypanosoma cruzi serology; additional organs: megacolon, cardiomyopathy, megarectum"], ["Distal Esophageal Spasm", "Preserved LES relaxation distinguishes from Type III achalasia; corkscrew appearance on barium"], ["Opioid-induced dysmotility", "Chronic opioid use history; may mimic achalasia manometrically"], ["Post-surgical pseudoachalasia", "After fundoplication or gastric banding; identical manometric pattern"], ["Paraneoplastic achalasia", "Rare; circulating antineuronal antibodies (e.g., anti-Hu); no direct tumor infiltration"], ], col_widths=[W*0.28, W*0.72] )) story.append(Spacer(1, 0.2*cm)) # ── 7. TREATMENT ─────────────────────────────────────────────────────────── story.append(section_header("7. Treatment")) story.append(Spacer(1, 0.2*cm)) story.append(callout_box( "Since the underlying neuropathology cannot be corrected, treatment aims to reduce LES pressure, " "allowing gravity-assisted esophageal emptying. Options range from pharmacologic (temporizing) to " "endoscopic and surgical (definitive)." )) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.1 Pharmacologic Therapy (Temporizing Only)", h2_style)) story.append(make_table( ["Agent", "Mechanism", "Dose / Notes"], [ ["Nifedipine (sublingual)", "Ca²⁺ channel blocker → smooth muscle relaxation → ↓ LES pressure", "30–40 mg/day before meals; side effects: flushing, orthostasis, edema"], ["Isosorbide dinitrate (sublingual)", "Nitrate → NO → smooth muscle relaxation", "Side effects: headache (common), tolerance develops"], ["Sildenafil", "PDE-5 inhibitor → ↑ cGMP (via NO) → ↓ LES pressure", "50 mg; effect peaks 15–20 min, lasts <1 hour; limited by cost/side effects"], ], col_widths=[W*0.24, W*0.42, W*0.34] )) story.append(Paragraph("All pharmacologic options are considered temporizing. Placebo-controlled evidence is minimal.", body_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.2 Botulinum Toxin Injection (Endoscopic)", h2_style)) for b in [ "80–100 units injected into 4 quadrants of the LES via sclerotherapy catheter", "Mechanism: irreversibly blocks ACh release from presynaptic cholinergic terminals", "Initial response in ~66%; minimal continued efficacy at 1 year", "Repeat injections cause local fibrosis, ultimately limiting this approach", "Doses >100 units do not improve efficacy", "Best reserved for elderly or frail patients who are poor candidates for definitive treatment", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.3 Pneumatic Dilation (Endoscopic)", h2_style)) for b in [ "Uses Rigiflex balloons (3.0, 3.5, 4.0 cm) to mechanically disrupt LES circular muscle", "Requires dilation to ≥3 cm for lasting benefit; smaller dilations provide only temporary relief", "Fluoroscopic guidance; outpatient under conscious sedation", "Success rate ~90% (comparable to LHM); perforation risk ~1%", "Preferred initial therapy for Type II achalasia (100% success in European Achalasia Trial)", "Only 40% success in Type III achalasia", "Can be performed sequentially (3.0 → 3.5 → 4.0 cm) if initial dilation insufficient", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.4 Laparoscopic Heller Myotomy (LHM)", h2_style)) for b in [ "Division of the LES circular muscle; combined with partial fundoplication (Dor or Toupet) to prevent post-procedure GERD", "Success rate ~87–92%", "Preferred for Type III achalasia (86% success vs. 40% for dilation)", "European Achalasia Trial (200 patients, RCT): no significant difference between pneumatic dilation and LHM at 2 years (92% vs 87%)", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.5 Per Oral Endoscopic Myotomy (POEM)", h2_style)) for b in [ "Endoscopic technique: submucosal tunnel created in mid-esophagus → selective circular myotomy extending 2 cm onto gastric cardia", "Success rate >90%, comparable to or better than LHM", "Meta-analysis (POEM n=1,958 vs. LHM n=5,834): POEM more effective for dysphagia short-term, but OR 9.31 for erosive esophagitis", "RCT: 92% remission with POEM vs. 70% with pneumatic dilation at 1 year (p<0.01)", "Key advantage for Type III: myotomy length can be extended the full length of the spastic segment (avg 13.5 cm)", "Main disadvantage: significantly higher rate of post-procedure GERD/erosive esophagitis", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.15*cm)) story.append(Paragraph("7.6 Treatment Selection by Subtype", h2_style)) story.append(make_table( ["Subtype / Patient", "Preferred Treatment", "Rationale"], [ ["Type I", "Pneumatic dilation or LHM", "Comparable efficacy; local expertise and patient preference guide choice"], ["Type II", "Pneumatic dilation (first-line)", "100% success in European trial; lower cost; comparable perforation risk to LHM"], ["Type III", "LHM or POEM (preferred)", "Poor response to dilation (40%); myotomy addresses spastic segment"], ["Elderly / frail", "Botulinum toxin injection", "Avoids procedural risk; repeat injections as needed"], ["End-stage / sigmoid esophagus", "Consider esophagectomy", "Massively dilated sigmoid esophagus may not respond to LES-reducing therapies"], ], col_widths=[W*0.24, W*0.30, W*0.46] )) story.append(Spacer(1, 0.2*cm)) # ── 8. COMPLICATIONS ─────────────────────────────────────────────────────── story.append(section_header("8. Complications")) story.append(Spacer(1, 0.2*cm)) story.append(make_table( ["Complication", "Details"], [ ["Aspiration pneumonia", "Up to 10% with advanced disease; can be the presenting complaint; results from nocturnal regurgitation"], ["Stasis esophagitis / Candida", "From retained food; esophageal acidification from bacterial fermentation"], ["Epiphrenic diverticulum", "Pulsion diverticulum from increased intraluminal pressure"], ["Squamous cell carcinoma", "17-fold increased risk vs. age-matched controls; absolute risk ~0.15%; develops in massively dilated esophagus after many years. ASGE does not recommend routine surveillance; if considered, begin 15 years after symptom onset"], ["Post-treatment GERD", "Particularly after POEM (OR 9.31 for erosive esophagitis) and LHM without fundoplication"], ["Esophageal perforation", "~1% risk with pneumatic dilation and LHM; requires immediate evaluation"], ], col_widths=[W*0.30, W*0.70] )) story.append(Spacer(1, 0.2*cm)) # ── 9. TREATMENT FAILURE ─────────────────────────────────────────────────── story.append(section_header("9. Evaluation of Treatment Failure")) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "Persistent dysphagia after treatment suggests treatment failure. Evaluate with:", body_style )) for b in [ "Endoscopy — esophagitis, stricture, paraesophageal hernia, anatomic deformity", "High-resolution impedance manometry — persistent sphincter dysfunction, distal spasm, esophageal pressurization", "Functional luminal imaging probe (FLIP) — assess distensibility of the EGJ", "Fluoroscopic timed barium esophagogram — quantify emptying and morphology", ]: story.append(Paragraph(f"• {b}", bullet_style)) story.append(Spacer(1, 0.3*cm)) story.append(HRFlowable(width=W, thickness=1, color=colors.HexColor("#aaaaaa"), spaceAfter=6)) story.append(Paragraph( "Sources: Sleisenger & Fordtran's Gastrointestinal and Liver Disease (10e) · Harrison's Principles of Internal Medicine (22E, 2025) · " "Sabiston Textbook of Surgery · Current Surgical Therapy (14e) · European Achalasia Trial (Lancet, 2014) · " "Chicago Classification v4.0 (Neurogastroenterol Motil, 2021)", source_style )) doc.build(story) print(f"PDF generated: {OUTPUT}") PYEOF python3 /tmp/workspace/achalasia/generate_pdf.py

Editing File

~/achalasia/generate_pdf.py

Successfully replaced 1 instance(s) of the string in '/tmp/workspace/achalasia/generate_pdf.py'

Running Command

python3 /tmp/workspace/achalasia/generate_pdf.py

Your PDF is ready:

Achalasia

PDF Document · PDF

The document covers all 9 sections in a clean, formatted layout with:

Color-coded section headers
All tables (Chicago Classification, Eckardt Score, clinical features, differential diagnosis, treatment selection, complications)
Two barium swallow images with captions
Callout boxes for clinical pearls (the "heartburn trap", treatment rationale)
Full source citations at the bottom

Al Grove Syndrome.

Reading File

Finding Sources

Searching PubMed

"Grove syndrome" acne keloidalis nuchae

Searching the Web

Grove syndrome dermatology clinical features treatment

Finding Sources

Searching PubMed

"transient acantholytic dermatosis" OR "Grover disease"

Reading Web Page

https://emedicine.medscape.com/article/1124347-clinical

Reading File

Loading Image

Reading File

I now have comprehensive information from Fitzpatrick's, Andrews', and Bolognini's Dermatology. Let me compile the full answer.

Note on the query: "Al Grove Syndrome" appears to be a voice/autocorrect variation of Grover's Disease (Transient Acantholytic Dermatosis). The answer below covers this condition in full.

Grover's Disease (Transient / Persistent Acantholytic Dermatosis)

Also known as: Transient Acantholytic Dermatosis (TAD) | Persistent Acantholytic Dermatosis

First described by Ralph W. Grover in 1970, who identified a sparse, predominantly truncal eruption of fragile vesicles rapidly becoming crusted keratotic erosions in older individuals. Despite the original "transient" label, many cases persist or recur, making the broader term "acantholytic dermatosis" more accurate.

Epidemiology

Incidence: relatively uncommon; likely under-diagnosed due to many oligosymptomatic or transient cases
Most common in fair-skinned (White) men over age 40-50; male:female ratio approximately 3:1
Strong association with solar (photo) damage to the skin
May affect younger individuals and females, though less commonly
Fitzpatrick's Dermatology

Etiology and Pathogenesis

The exact cause remains unknown. No mutation in ATP2A2 (the gene mutated in Darier disease, the closest histological mimic) has been identified in Grover disease despite sharing many features.

Proposed mechanisms:

Impairment of keratinocytic cholinergic receptors - suggested by the observation that varenicline (a partial nicotinic ACh receptor agonist) triggered onset in one reported case
Desmosomal disruption - electron microscopy shows clumping of keratin filaments and loss/internalization of desmosomes, linking it to the broader group of acantholytic disorders
Possible involvement of calcium pump dysfunction (shared with Darier and Hailey-Hailey disease), though unconfirmed

Recognized triggers and associations:

Category	Examples
Sweating / heat	Febrile illness, bed confinement, hot weather, excessive exercise
Dry skin / cold	Winter flares in older men with xerosis
UV / ionizing radiation	Sun exposure, radiation therapy
Drugs	Cetuximab, chemotherapy agents, EGFR inhibitors; drug-induced cases reported
Inflammatory dermatoses	Atopic eczema (5x more common in TAD patients vs. controls), xerosis
Systemic illness	Renal failure, HIV infection, hematologic malignancies, solid carcinomas
Post-transplant	Kidney, liver, heart, bone marrow transplant recipients
Hospitalization	Strict bed rest is an independent risk factor

Fitzpatrick's Dermatology; Andrews' Diseases of the Skin

Clinical Features

Grover disease - scattered itchy erythematous papules on sun-damaged trunk of a 60-year-old man

Grover disease: itchy papules on the trunk resembling folliculitis in a 60-year-old man. - Fitzpatrick's Dermatology

Primary lesions:

1-3 mm monomorphous scaly papules, erythematous to red-brown with variable hyperkeratosis
Papulovesicles (more characteristic); rarely bullae
Occasional acneiform, pustular, or eczematous plaques
Lesions remain discrete and do not coalesce in most cases

Distribution:

Predominantly the chest, upper back, shoulder girdle, upper abdomen
Neck and proximal limbs may be involved
Mucous membranes and acral sites are spared
Rarely zosteriform or unilateral distribution (may represent segmental Darier disease)

Symptoms:

Pruritus - the hallmark symptom; often intense and out of proportion to visible lesions
Some patients are completely asymptomatic (incidental finding)
Lesions may bleed; sweating and heat typically worsen itching

Course:

Transient form: clears within weeks to months
Persistent form: itch persists with fluctuating intensity for years, especially in older adults
Recurrences are common; truly transient cases may be the minority

Histopathology

The histologic picture shows acantholysis (loss of intercellular connections between keratinocytes) in patterns that can mimic other acantholytic disorders. Crucially, multiple patterns may be found in a single biopsy specimen - this combination is very suggestive of Grover disease.

Histology of Grover disease - A: Hailey-Hailey-like pattern with acantholysis and epidermal hyperplasia; B: Pemphigus-like suprabasal acantholytic cleavage

Histology: A = Hailey-Hailey-like pattern with detached keratinocytes, focal spongiosis, and epidermal hyperplasia. B = Pemphigus-like suprabasal acantholytic cleavage. - Fitzpatrick's Dermatology

Five recognized histologic subtypes:

Pattern	Features	What it resembles
Darier-like (most common)	Acantholytic dyskeratosis; corps ronds and grains	Darier disease
Pemphigus vulgaris-like	Suprabasal acantholytic cleavage	PV
Pemphigus foliaceus-like	Subcorneal/superficial acantholysis	PF
Hailey-Hailey-like	Extensive "dilapidated brick wall" acantholysis	Hailey-Hailey disease
Spongiotic	Spongiosis with variable acantholysis	Eczema

Key immunofluorescence finding: Direct immunofluorescence (DIF) is negative or nonspecific - no immunoglobulin or complement deposits in the epidermis (unlike pemphigus). This is a critical distinguishing feature.

Fitzpatrick's Dermatology; Andrews' Diseases of the Skin

Diagnosis

Diagnosis is primarily clinical in classic presentations; confirmed by skin biopsy (punch biopsy) when in doubt.

Tzank smear: Grover himself confirmed the diagnosis by documenting acantholytic and dyskeratotic cells (corps ronds and grains) on cytologic preparation
DIF: usually performed to exclude pemphigus and other autoimmune blistering diseases - expected to be negative in Grover disease
Dermoscopy: polygonal/star-shaped yellowish-brownish areas (corresponding to hyperparakeratosis) with a peripheral whitish halo (orthokeratosis/hypergranulosis)
Consider workup for underlying hematologic malignancy given the association, particularly in new or severe presentations

Differential Diagnosis

Condition	Key distinguishing features
Darier disease	Autosomal dominant (ATP2A2 mutation); family history; nail changes (red/white streaks, V-shaped nicks); mucosal involvement; childhood onset; no spontaneous resolution
Hailey-Hailey disease	Autosomal dominant (ATP8A1); intertriginous distribution; maceration; blistering in flexures
Pemphigus vulgaris/foliaceus	Positive DIF; circulating anti-desmoglein antibodies (ELISA); mucosal erosions (PV)
Scabies	Burrows; interdigital spaces; household contacts affected
Folliculitis	Perifollicular; gram stain/culture positive
Miliaria rubra (heat rash)	Associated with fever/sweat occlusion; no acantholysis on histology
Papular eczema / prurigo	No acantholysis; responds to topical steroids more reliably
Galli-Galli disease	Acantholytic variant of Dowling-Degos; reticulate pigmentation; family history
Insect bites	Grouping; exposure history; eosinophils on biopsy
Dermatitis herpetiformis	Extensor distribution; positive IgA DIF; celiac association

Fitzpatrick's Dermatology

Treatment

Treatment is symptomatic and often challenging; response can be disappointing. The key first step is avoiding precipitating factors.

General measures:

Avoid heat, sweating, tight clothing, sun exposure, and topical irritants
Use mild soaps and light-colored cotton fabrics
Adequate skin hydration

Topical therapy:

Agent	Notes
Emollients / moisturizers (camphor, menthol)	First-line; soothing, reduce xerosis trigger
Topical corticosteroids (mid-potency)	~50% of patients respond; reduce inflammation and pruritus
Topical calcipotriol/tacalcitol	Multiple reports of efficacy; alters keratinocyte differentiation
Topical retinoids	Reduce epidermal dyskeratosis
Antipruritic agents (pramoxine, menthol)	Symptomatic relief
Topical antibiotics	Some benefit reported

Systemic therapy (for persistent/severe disease):

Agent	Notes
Oral retinoids (acitretin, isotretinoin)	Most evidence for persistent disease; acitretin + phototherapy combination reported
Systemic corticosteroids	Sustained remission reported; short courses for acute flares
Methotrexate	Used for recalcitrant disease
Dapsone	Successful in some patients

Physical therapies:

Narrowband UVB - can produce clearing
PUVA - may cause initial flare, then slow clearance
Photodynamic therapy (5-ALA + red light) - reported as successful in recalcitrant cases
Grenz rays

Emerging / biologic therapy:

Dupilumab (anti-IL-4/IL-13): Multiple recent reports of benefit, including a 2021 JAMA Dermatology case series; improvement with IL-4/IL-13 blockade is consistent with the observation that many Grover disease patients meet criteria for atopic dermatitis. A 2026 study in JAAD confirmed efficacy and tolerability of off-label dupilumab in acantholytic dyskeratotic disorders.
Rituximab: Clearance of TAD has been reported in patients receiving rituximab for lymphoma

Hospitalization-associated Grover disease often improves simply with hospital discharge, fever control, and resuming normal activity. This is an important and often overlooked treatment "intervention."

Fitzpatrick's Dermatology; Andrews' Diseases of the Skin; Medscape eMedicine

Prognosis

Transient form: spontaneous resolution within weeks to months (as originally described by Grover)
Persistent form: fluctuating pruritic course for years; more common in older adults; the more clinically significant presentation
Association with internal malignancy is likely coincidental (related to hospitalization or immunosuppression rather than direct paraneoplastic causation)
Generally not life-threatening; quality of life impact is primarily from intractable pruritus

Sources: Fitzpatrick's Dermatology (9e) · Andrews' Diseases of the Skin (13e) · Bolognini Dermatology (5e) · Weaver & Bergfeld, Arch Pathol Lab Med 2009 · Butler et al., JAMA Dermatol 2021 - Dupilumab for Grover Disease · Harmon et al., J Invest Dermatol 2025 - Calcium pumps in acantholytic disorders

This is a shared conversation. Sign in to Orris to start your own chat.